Hormone therapy may prevent age-related hyperkyphosis in women

Published On 2018-02-24 14:30 GMT   |   Update On 2018-02-24 14:30 GMT
The risk factors of Hyperkyphosis are low bone mineral density, bone loss, and vertebral fractures and it leads to poor physical function, falls, fractures, and earlier mortality.It has been observed that Menopausal hormone therapy (HT) reverses bone loss and prevents vertebral fractures.Dr.Woods, Gina N of North American Menopause Society and associates conducted a study to evaluate whether it reduces the risk of developing hyperkyphosis.The researchers found that Women having continuous or remote past HT had less pronounced kyphosis than never-users by their mid-eighties, suggesting a possible role for Hormone therapy as it may prevent age-related hyperkyphosis in women.The study has been published in Menopause, the journal of The North American Menopause Society (NAMS).

It is well documented that the significant declines in estrogen experienced during the menopause transition contribute to an accelerated bone loss. Hormone therapy reverses bone loss and helps prevent fractures.During the first three years of HT use, bone density has been shown to increase steadily and then is maintained during continued use.


Given that hyperkyphosis is also associated with bone loss and vertebral fractures, the authors of the article "Patterns of menopausal hormone therapy use and hyperkyphosis in older women" hypothesised that HT may also be effective in helping prevent exaggerated spine curvature, sometimes called dowager's hump.


The study on which the article is based involved more than 9,700 women aged 65 years and older who were evaluated over a 15-year period.


Women who reported continuous or remote past HT use had less pronounced kyphosis by the time they were in their mid-80s than never-users, supporting the argument for HT as a possible early post-menopause treatment for women concerned about their posture and fracture risk.


Beyond its adverse aesthetic effects, hyperkyphosis is associated with the poor physical function, an increased risk of falls and fractures, and earlier mortality.


"Women who reported the early use of HT were less likely to develop age-related kyphosis, and the protective benefits continued even after stopping HT", said Dr. JoAnn Pinkerton, NAMS executive director. "This supports a benefit of prescribing HT close to menopause".


For further Reference log on to : doi: 10.1097/GME.0000000000001070
Article Source : ANI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News